Daily subcutaneous (SC) injections of the investigational drug abaloparatide-SC (80 mcg) for 18 months significantly decrease the risk of vertebral and nonvertebral fracture compared with placebo in postmenopausal women. We examined the efficacy of abaloparatide-SC … Leer más
Urolithiasis.2017 Jun;45(3):279-283. doi: 10.1007/s00240-016-0909-2 Más información Girón-Prieto MS, Del Carmen Cano-García M, Poyatos-Andújar A, Arias-Santiago S, de Haro-Muñoz T, Arrabal-Martín M, Arrabal-Polo MÁ
This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of … Leer más
Transplantation. 2017 Jun;101(6):1290-1294. doi: 10.1097/TP.0000000000001328 Más información Pérez-Sáez MJ, Herrera S, Prieto-Alhambra D, Nogués X, Vera M, Redondo-Pachón D, Mir M, Güerri R, Crespo M, Díez-Pérez A, Pascual J
The relative efficacy and harms of balloon kyphoplasty (BK) for treating vertebral compression fractures (VCF) are uncertain. The clinical importance of the greater improvements with BK versus NSM is unclear, may be due to placebo … Leer más
J Bone Miner Res. 2017 May;32(5):889-891. doi: 10.1002/jbmr.3141. Epub 2017 Apr 6. Más información Delgado-Calle J, Bellido T.
Osteoarthritis (OA) is characterized by degenerative changes in the whole joint leading to physical disability in the elderly population. This condition is associated with altered bone metabolism in subchondral areas suggesting that therapeutic strategies aimed … Leer más
If oversuppression of bone turnover explained the association between bisphosphonate use and atypical subtrochanteric femur fractures (AFF), this could be reversed with anabolic treatment such as teriparatide. They conducted a prospective, open-label study in patients … Leer más
Type 1 and type 2 diabetes are generally accepted to be associated with increased bone fracture risk. However, the pathophysiological mechanisms of diabetic bone disease are poorly understood, and whether the associated increased skeletal fragility … Leer más
A case series of six women with postmenopausal osteoporosis who had received continuous denosumab for 7 years and were then given a single infusion of zoledronate (5 mg) is reported. During denosumab treatment, bone mineral density (BMD) … Leer más
